Brazil officials signed off this week on funding for a late-stage dengue vaccine trial, adding another twist to the global dengue vaccine competition amid the launch of the first approved jab.
Sanofi's dengue vaccine gets first Asian approval with more discussions underway
The Philippines' FDA approved Sanofi's first-of-its-kind dengue fever vaccine, Dengvaxia, on Tuesday. And on the same day, India's Economic Times reported that the government there is exploring opportunities to accelerate marketing authorization for the vaccine, considering exempting it from large local clinical trials.
U.S. Army, Hawaii Biotech join for dengue vaccine effort
Seeking a dengue fever vaccine that can offer broad protection in a short time, the U.S. Army has awarded Hawaii Biotech a Phase I contract to support the company's work against the "potentially mission-aborting" disease, according to a press release.
As it works to introduce its dengue vaccine in endemic countries around the world, Sanofi Pasteur this week touted efficacy results from two Phase III studies in a move to help build the case for wide uptake.
After the company's largest investment ever in the development of a vaccine, Sanofi Pasteur's dengue vaccine launch is ready for this year, and it'll be closely watched as the group introduces the jab in a manner reversed from traditional launches.
Last September, Takeda announced it would be putting vaccines into their own specialty business unit to "accelerate the globalization" of the business. And now, it's positioning the unit geographically to do the same.
Sanofi's $1.5B dengue vaccine shows Phase III promise, but questions linger
Capping a 20-year effort to develop the world's first dengue fever vaccine, Sanofi has come through with positive results from a sweeping Phase III trial, but its candidate is not quite a panacea for the often deadly disease.
Sanofi turns out positive PhIII data in quest for dengue blockbuster
After more than 20 years of development, Sanofi finally has some Phase III data for its dengue vaccine. The first of two Phase III studies hit its primary clinical endpoint, which should push it closer toward making the candidate--and its blockbuster aspirations--a reality.
Sanofi and Pitt join up to test wannabe dengue blockbuster
Sanofi's dengue fever candidate is on the verge of regulatory applications after 20 years in the lab and more than $1.4 billion spent on R&D.; Now the pharma giant has forged a new collaboration to help assess the jab's postintroduction effectiveness.
Sanofi bets big on dengue with eyes on a blockbuster
After 20 years in the lab and $1.4 billion in R&D; costs, Sanofi's in-development dengue fever vaccine is on the verge of regulatory applications, and, despite a few clinical hiccups, the drugmaker told Reuters it believes it has a blockbuster on its hands.